Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) and Prenetics Global (NASDAQ:PRE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
Volatility & Risk
Neuphoria Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Prenetics Global has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Neuphoria Therapeutics and Prenetics Global, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neuphoria Therapeutics | 2 | 0 | 2 | 0 | 2.00 |
| Prenetics Global | 1 | 0 | 1 | 0 | 2.00 |
Profitability
This table compares Neuphoria Therapeutics and Prenetics Global’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neuphoria Therapeutics | N/A | -53.17% | -36.15% |
| Prenetics Global | -60.70% | -30.12% | -23.87% |
Insider & Institutional Ownership
15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 25.0% of Prenetics Global shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by insiders. Comparatively, 7.8% of Prenetics Global shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Neuphoria Therapeutics and Prenetics Global”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neuphoria Therapeutics | $15.65 million | 1.41 | -$370,000.00 | ($4.88) | -0.84 |
| Prenetics Global | $30.62 million | 8.17 | -$46.30 million | ($2.03) | -7.33 |
Neuphoria Therapeutics has higher earnings, but lower revenue than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Prenetics Global beats Neuphoria Therapeutics on 7 of the 13 factors compared between the two stocks.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
About Prenetics Global
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.
Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
